Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session

RATIONALE: A substantial number of breast cancer patients with an overexpression of the human epidermal growth factor receptor 2 (HER2) have residual disease after neoadjuvant therapy or become resistant to trastuzumab. Photodynamic therapy (PDT) using nanobodies targeted to HER2 is a promising trea...

Full description

Saved in:
Bibliographic Details
Published in:J Control Release
Main Authors: Deken, Marion M., Kijanka, Marta M., Hernández, Irati Beltrán, Slooter, Maxime D., de Bruijn, Henriette S., van Diest, Paul J., van Bergen en Henegouwen, Paul M.P., Lowik, Clemens W.G.M., Robinson, Dominic J., Vahrmeijer, Alexander L., Oliveira, Sabrina
Format: Artigo
Language:Inglês
Published: 2020
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7116241/
https://ncbi.nlm.nih.gov/pubmed/32330574
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jconrel.2020.04.030
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items